Abstract: The present invention relates to a complex of agomelatine and to preparation thereof. The hydrogen halide complex of agomelatine obtained through the present method is more soluble, more stable, and of higher purity than agomelatine itself, making it more suitable to be used in pharmaceutical preparation. Using this method, product of high purity can be obtained through a simple process, without having to incur further complicated steps.
Abstract: Compounds of formula (I): wherein: R1 and R2, which may be the same or different, each represent a hydrogen or halogen atom or an alkyl, alkoxy, alkylthio, acyl, alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, cyano, nitro, amino, substituted or unsubstituted aminocarbonyl, aminosulphonyl, alkylsulphonylaminoalkyl, N-hydroxy-carboximidamide or benzyloxy group, R3 represents a hydrogen atom or an alkyl, cycloalkyl or cycloalkylalkyl group, R4 represents a hydrogen atom or a substituted or unsubstituted alkyl group Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator and/or an NMDA receptor antagonist.
Type:
Grant
Filed:
March 19, 2010
Date of Patent:
August 7, 2012
Assignee:
Les Laboratories Servier
Inventors:
Alexis Cordi, Patrice Desos, Pierre Lestage, Laurence Danober
Abstract: Compounds of formula (I): wherein: R1 represents an alkyl, cycloalkyl or cycloalkylalkyl group, R2 represents a linear or branched (C1-C6)alkyl group, and n represents from 1 to 6. Medicaments.
Type:
Grant
Filed:
October 17, 2007
Date of Patent:
August 23, 2011
Assignee:
Les Laboratories Servier
Inventors:
Pascal Marchand, Vincent Babonneau, Sylvie Piessard, Muriel Duflos, Jean Albert Boutin, Valérie Audinot, Philippe Delagrange, Daniel-Henri Caignard
Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, on its own or in association, in obtaining medicaments intended for the treatment of bipolar disorders, especially bipolar disorders of types I and II, and more especially bipolar disorders of type I.
Abstract: The invention relates to a method of screening and identifying modulators of the protein interaction between new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.
Type:
Grant
Filed:
January 31, 2006
Date of Patent:
April 19, 2011
Assignees:
Les Laboratories Servier, Hybrigenics
Inventors:
Olivier Geneste, John Hickman, Jean-Christophe Rain
Abstract: A ?-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Abstract: Crystalline form III of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
Abstract: Compound of formula (I): wherein: represents 1-oxidopyridyl substituted by the remainder of the molecule in any one of the positions 2, 3 and 4, m and n, which may be identical or different, each represent an integer of from 1 to 3, R1 represents hydrogen or alkyl, R2 and R3, which may be identical or different, each represent an atom or group selected from hydrogen, halogen, alkyl, hydroxy, acyloxy and alkoxy, or, together with the carbon atom carrying them, form a cycloalkane having from 3 to 6 carbon atoms, R4 and R5 each represent hydrogen, or are adjacent and, together with the carbon atoms carrying them, form a benzo ring, Ar represents aryl or heteroaryl. Medicinal products containing the same which are useful as thrombin inhibitors.
Type:
Grant
Filed:
March 14, 2005
Date of Patent:
March 3, 2009
Assignee:
Les Laboratories Servier
Inventors:
Guillaume De Nanteuil, Philippe Gloanec, Jean-Gilles Parmentier, Alain Benoist, Alain Rupin, Marie-Odile Vallez, Tony Verbeuren
Abstract: The invention relates to the identification of a new peptide interacting with the anti-apoptotic proteins Bcl-2, Bcl-W and/or Bcl-XL, and also to screening methods allowing identification of modifiers of those interactions.
Type:
Grant
Filed:
August 4, 2004
Date of Patent:
December 2, 2008
Assignee:
Les Laboratories Servier
Inventors:
Olivier Geneste, John Hickman, Richard Bennett, Jean-Christophe Rain
Abstract: A compound selected from those of formula (1): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl or (C1-C6)-trihaloalkoxy group or an optionally substituted amino group, R7 represents a hydrogen atom, a (C1-C6)alkyl group or an arylalkyl group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of ?4?2 receptors.
Type:
Application
Filed:
February 15, 2008
Publication date:
June 19, 2008
Applicant:
LES LABORATORIES SERVIER
Inventors:
Solo Goldstein, Claude Guillonneau, Yves Charton, Brian Lockhart, Pierre Lestage
Abstract: Crystalline form V of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
Abstract: Process for the synthesis of (2S)-indoline-2-carboxylic acid of formula (I): Application in the synthesis of perindopril and its pharmaceutically acceptable salts.
Abstract: A compound selected from those of formula (I): wherein: W1, with the carbon atoms to which it is bonded, represents phenyl or pyridyl, Z represents a group selected from hydrogen, halogen, linear or branched (C1-C6)alkyl, aryl, aryl-(C1-C6)alkyl, aryloxy, aryl-(C1-C6)alkoxy, hydroxy and linear or branched (C1-C6)alkoxy, R1 is as defined in the description, R2 represents hydrogen or —CH2CH2O—R8, R3 and R4 each represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl, n represents an integer of from 1 to 6 inclusive, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.
Type:
Grant
Filed:
October 17, 2003
Date of Patent:
December 25, 2007
Assignee:
Les Laboratories Servier
Inventors:
Gérard Coudert, Franck Lepifre, Daniel-Henri Caignard, Pierre Renard, John Hickman, Alain Pierre, Laurence Kraus-Berthier
Abstract: Compound of formula (I): wherein: R1 represents aryl, heteroaryl or alkyl which is optionally substituted, or a group of formula —(CO)—CR6R7NR8R9 wherein R6, R7, R8 and R9 are as defined in the description, R2 represents hydrogen or alkyl, R3 represents hydrogen or optionally substituted alkyl, R4 represents a saturated or unsaturated, 7- to 15-membered bicyclic system or optionally substituted alkyl, or R3 and R4, together with the carbon atom carrying them, form a saturated or unsaturated, 3- to 18-membered, mono-, bi- or tri-cyclic system optionally containing one or more hetero atoms selected from O, S and N and optionally substituted, n represents 1 or 2, Ar represents aryl or heteroaryl, R5 represents amino, guanidino, cyano or amidino which is optionally substituted, its optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in pathological conditions involving activated protein C.
Type:
Grant
Filed:
February 17, 2003
Date of Patent:
September 4, 2007
Assignee:
Les Laboratories Servier
Inventors:
Guillaume De Nanteuil, Philippe Gloanec, Tony Verbeuren, Alain Rupin